Yamin Shu

Yamin Shu

Auto-generated profile, based on publicly available information

Yamin Shu

Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
YSYamin Shu
Yamin Shu
XHXucheng He
Xucheng He
YLYanxin Liu
Yanxin Liu
PWPan Wu
Pan Wu
QZQilin Zhang
Qilin Zhang
Background: Olaparib, the world’s first poly ADP-ribose polymerase (PARP) inhibitor (PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer by FDA. The current study was to assess olaparib-related adverse events (AEs) of real-world through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were employed to quantify the signals of olaparib-associated AEs. Results: Out of 8,450,009 reports collected from the FAERS database, 6402 reports of olaparib-associated AEs were identified. A total of 118 significant disproportionality preferred terms (PTs) conforming to the four algorithms simultaneously were retained. The most common AEs included anemia, thrombocytopenia, nausea, decreased appetite, blood creatinine increased and dermatomyositis, which were corresponding to those reported in the specification and clinical trials. Unexpected significant AEs as interstitial lung disease, Pneumocystis jirovecii pneumonia, folate deficiency, renal impairment and intestinal obstruction might also occur. The median onset time of olaparib-related AEs was 61 days (interquartile range [IQR] 14– 182 days), and most of the cases occurred within the first 1 month after olaparib initiation. Conclusion: Results of our study were consistent with clinical observations, and we also found potential new and unexpected AEs signals for olaparib, suggesting prospective clinical studies were needed to confirm these results and illustrate their relationship. Our results could provide valuable evidence for further safety studies of olaparib.

17 February 2025 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
YDYiling Ding
Yiling Ding
CWChunping Wang
Chunping Wang
YSYamin Shu
Yamin Shu
JWJinglin Wang
Jinglin Wang
QZQilin Zhang
Qilin Zhang
The addition of cadonilimab to first-line platinum-based chemotherapy with or without bevacizumab significantly improved progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. However, the economic value of using this novel therapy for this indication is currently unknown. The aim of this study is to evaluate the cost-effectiveness of the addition of cadonilimab to first-line standard chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer from the perspective of Chinese healthcare system. A partitioned survival model was constructed to compare the cost-effectiveness of cadonilimab versus placebo in patients enrolled in the COMPASSION-16 trial. Cost, life-year, quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB) were calculated for 2 treatment strategies. Sensitivity, scenario, and subgroup analyses, and value of information analysis (EVPI) were performed. Cadonilimab provided an additional 1.18 QALYs and $89,528.64 compared with placebo, which resulted in an ICER of $75,944.56/QALY. At the willingness-to-pay threshold of $38,042.49/QALY, INHB was estimated to be −1.17 QALYs, while INMB amounted to −$44,681.55 and EVPI was calculated as $71.40/person. Sensitivity analyses revealed that the model was most sensitive to hazard ratio (HR) for OS and PFS, and the probability of cadonilimab being cost-effective was 0.70%. To achieve cost-effectiveness, the price of cadonilimab must be reduced by approximately 50%. Subgroup analysis found that all subgroups unfavored cadonilimab by varying the HR for OS and PFS. Scenario analyses showed using life-year as effectiveness, altering time horizon and selection of survival analysis did not reverse results. Although the use of cadonilimab resulted in clinical benefit, it was not deemed cost-effective as a first-line therapy for persistent, recurrent, or metastatic cervical cancer in China. Lowering the price of cadonilimab may enhance its cost-effectiveness.

1 April 2026 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
FSFenghao Shi
Fenghao Shi
STShuhua Tan
Shuhua Tan
YSYamin Shu
Yamin Shu
TLTianyi Liu
Tianyi Liu
YXYan Xia
Yan Xia
SHSheng Han
Sheng Han
Aim: Diabetic macular edema (DME) is one of the leading causes of vision impairment in diabetic patients. The aim of this study was to evaluate the cost-effectiveness of faricimab (Vabysmo ® ), the first bispecific antibody targeting VEGF-A and ANG-2, for treating DME in China. Materials & methods: We conducted a cost-effectiveness analysis from the perspective of the Chinese health system using a Markov model to simulate long-term outcomes in DME patients. The model population was based on the Chinese subgroup from the RHINE trial, with a mean starting age of 58.7 years. Faricimab, administered according to a personalized treatment interval regimen following four initial monthly injections, was compared with aflibercept (every 8 weeks) and with ranibizumab and conbercept (both following a pro-re nata dosing regimen). The model incorporated clinical efficacy, adverse events, quality-adjusted life years and direct costs. Extensive sensitivity analyses (one-way and probabilistic) were performed to assess the robustness of the findings. Results: Over 20 years, faricimab gained 0.42, 0.61, 0.80 incremental quality-adjusted life years compared with aflibercept, conbercept, ranibizumab, while reducing treatment costs by 33,315 Chinese Yuan (CNY), 59,061 CNY and 12,314 CNY, respectively. Sensitivity analyses confirmed the robustness of these results, consistently demonstrating faricimab as a dominant and cost-effective treatment option for DME. Conclusion: This first Chinese cost-effectiveness study of faricimab for DME shows it enhances visual outcomes and reduces costs, supporting its adoption and providing evidence for healthcare decision-making on reimbursement and resource allocation.

1 January 2025 in Dermatologic Therapy
Verified
Journal Article
Open access
YDYiling Ding
Yiling Ding
ZWZhen Wang
Zhen Wang
YSYamin Shu
Yamin Shu
YTYing Tang
Ying Tang
QZQilin Zhang
Qilin Zhang
Objective: Recognized as the primary treatment for unresectable hepatocellular carcinoma (HCC) and as an approved therapeutic agent for renal cell carcinoma (RCC) and differentiated thyroid carcinoma (DTC), sorafenib is often limited in long‐term clinical application due to dermatologic toxicity, which may necessitate dose modifications or even treatment discontinuation. The present study sought to comprehensively characterize these toxicities through mining of the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: Using FAERS reports collected between the first quarter (Q1) of 2018 and Q1 of 2023, we applied disproportionality analysis, calculating reporting odds ratios (RORs) to compare sorafenib‐related dermatologic toxicity with the overall database. Comparisons were made between serious and nonserious reports, followed by signal prioritization using a predefined scoring system. To evaluate the consistency of these findings, stratification analyses were undertaken. Moreover, univariate logistic regression was applied to investigate potential determinants of sorafenib‐related dermatologic AEs. Results: Reports of dermatologic toxicity accounted for 32.36% of the overall sorafenib reports during the study period, and 72 adverse events (AEs) were defined as sorafenib‐related dermatologic toxicity. Reports of sorafenib‐associated dermatologic toxicity indicated a median patient age of 64 years (interquartile range [IQR] 56–72) and a median time‐to‐onset (TTO) of 11 days (IQR: 0.5–37.5), with serious outcomes accounting for 89.07% of cases. Besides, 1, 15, and 16 AEs were identified as signals with strong, moderate, and weak clinical priority, respectively, all displaying an early failure pattern. Sex and reporter types were significant influencing factors for sorafenib‐associated dermatic AEs (male: OR = 0.667 [0.577–0.772], p < 0.01; healthcare professional: OR = 0.760 [0.661–0.874], p < 0.01). Conclusions: This study characterized the clinical features, TTO, severity profiles, clinical prioritization, and influencing factors of sorafenib‐associated dermatologic toxicities. The findings offer supportive evidence to aid clinicians in managing AEs, thereby enhancing patient adherence and therapeutic outcomes.